Ann: FY23 Full Year Results Announcement, page-29

Yes, it took me and a lot of others by surprise at just how big the drop was.

The drop was exacerbated by the fact that the company had over capitalised in anticipation of getting FebriDx approval by massively scaling up their production capacity at the Sarasota facility. Without the FDA approval and anticipated demand that would bring, their production capacity was a massive drain on resources putting them in a position where they potentially could have collapsed.

The quick moves by the company to slash spending, etc has fortuitously enabled us to still have a company to hold shares in and to now be looking at a decent recovery in share price.